# PDUFA dates November 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-11

> 457 FDA catalysts are dated in November 2026, including 12 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in November 2026?

PDUFA dates in November 2026: AQVESME™ (mitapivat, AGIO) on November 1, 2026; Karyopharm Therapeutics Inc. (KPTI) on November 10, 2026; NRX Pharmaceuticals, Inc. (NRXP) on November 10, 2026; MYQORZO® (aficamten, CYTK) on November 14, 2026; IGALMI® (dexmedetomidine, BTAIQ) on November 14, 2026; ivonescimab (SMMT) on November 14, 2026; and 6 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-11)

Source: Press release filed with the SEC (EX-99), accession 0001439222-26-000115, https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/fda-calendar/2026-11#answer

## PDUFA dates in November 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| November 1, 2026 | AGIOS PHARMACEUTICALS, INC. | AGIO | AQVESME™ (mitapivat) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm) |
| November 10, 2026 | Karyopharm Therapeutics Inc. | KPTI |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/d141618d8k.htm) |
| November 10, 2026 | NRX Pharmaceuticals, Inc. | NRXP |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/nrxp20260915_8k.htm) |
| November 14, 2026 | CYTOKINETICS INC | CYTK | MYQORZO® (aficamten) | Symptomatic Obstructive HCM | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm) |
| November 14, 2026 | BioXcel Therapeutics, Inc. | BTAIQ | IGALMI® (dexmedetomidine) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm) |
| November 14, 2026 | Summit Therapeutics Inc. | SMMT | ivonescimab |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm) |
| November 22, 2026 | Savara Inc | SVRA |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm) |
| November 22, 2026 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel | rare diseases, today | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm) |
| November 25, 2026 | Sanofi | SNY | venglustat |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm) |
| November 27, 2026 | BridgeBio Pharma, Inc. | BBIO | ribitol |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm) |
| November 30, 2026 | Cogent Biosciences, Inc. | COGT | bezuclastinib |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm) |
| November 30, 2026 | VERTEX PHARMACEUTICALS INC / MA | VRTX | povetacicept | immunoglobulin A nephropathy | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm) |

## All catalysts in November 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 1, 2026 | [AQVESME™ (mitapivat) PDUFA date](https://sec-api.dev/pdufa/mitapivat) | AGIO |  | scheduled | "•sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm)) |
| November 2026 | [ISEMBYLD (apitegromab) primary completion](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 | scheduled | "NCT05626855 (Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05626855)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar-I Disorder With Mania or Mania With Mixed Features | scheduled | "NCT06951698 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06951698)) |
| November 2, 2026 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA |  | completed, positive | "Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced positive topline data in its Phase 2a INFORM-MS trial with intranasal foralumab (a human, anti-CD3 monoclonal antibody) in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026114650/ea031046501ex99-1.htm)) |
| November 2, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_1.htm)) |
| November 2, 2026 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312526443644/crsp-ex99_1.htm)) |
| November 2, 2026 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, November 2, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company" or "Krystal") (NASDAQ: KRYS) today reported financial results for the third quarter ended September 30, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/exhibit991-3q26pressrelease.htm)) |
| November 2, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, Nov. 2, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000053/q3-2026xearningsrelease.htm)) |
| November 2, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| November 2, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000110/ebs202609-30ex99er.htm)) |
| November 2, 2026 | [Seaport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sptx/catalysts) | SPTX |  | completed | "Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2042347/000119312526442625/sptx-ex99_1.htm)) |
| November 2, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| November 2, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., November 2, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000021/earningsrelease-2nov26ex991.htm)) |
| November 2, 2026 | [Ifezuntirgene inilparvovec NDA/BLA acceptance](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed | "November 2, 2026, uniQure N.V. (the "Company") issued a press release announcing the U.S. Food and Drug Administration ("FDA") has accepted for review the Biologics License Application ("BLA") for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington's disease submitted under the Accelerated Approval pathway." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm)) |
| November 2, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)) |
| November 2, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000074/a2026q3_8-kxex991.htm)) |
| November 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT05723562 (A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05723562)) |
| November 2, 2026 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Cutaneous Lupus Erythematosus | completed | "NCT06015737 (A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015737)) |
| November 2026 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Melanoma | scheduled | "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06190951)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar Disorder Type I With Mania or Mania With Mixed Features | scheduled | "NCT06951711 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06951711)) |
| November 3, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000125/pfe-9272026xex99.htm)) |
| November 3, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026069093/exhibit991-93026earningspr.htm)) |
| November 3, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000074/exhibit991tarsus1132026.htm)) |
| November 3, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526444381/alks-ex99_1.htm)) |
| November 3, 2026 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/tm2629072d1_ex99-1.htm)) |
| November 3, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000035/amrx-q32026ex991.htm)) |
| November 3, 2026 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312526444410/d144290dex991.htm)) |
| November 3, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| November 3, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)) |
| November 3, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm)) |
| November 3, 2026 | [Latigo Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/ltgo/catalysts) | LTGO |  | completed | "Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2056611/000119312526448537/ltgo-ex99_1.htm)) |
| November 3, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026069493/q3268kex991.htm)) |
| November 3, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm)) |
| November 3, 2026 | [First Tracks Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/trax/catalysts) | TRAX |  | completed | "First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-ex99_1.htm)) |
| November 3, 2026 | [Beam Therapeutics Inc. earnings report](https://sec-api.dev/companies/beam/catalysts) | BEAM |  | completed | "Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000119312526444454/beam-ex99_1.htm)) |
| November 3, 2026 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000110465926122727/pahc-ex99d1.htm)) |
| November 3, 2026 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports Third Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)) |
| November 3, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026069106/q32026earningspr.htm)) |
| November 3, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000061/mirm-20261103xexx991.htm)) |
| November 3, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000107/ex991pressreleaseq32026.htm)) |
| November 3, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026069101/q32026earningsrelease.htm)) |
| November 3, 2026 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000162828026069115/q32026earningsrelease_final.htm)) |
| November 3, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526444225/idya-ex99_1.htm)) |
| November 3, 2026 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000119312526448532/krro-ex99_1.htm)) |
| November 3, 2026 | [WELTRUZA (weltruza) FDA approval](https://sec-api.dev/pdufa/weltruza) | TEVA |  | completed, approved | "The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| November 3, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000153/amgn-20260930earningsrelea.htm)) |
| November 3, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000073/q32026-ex991earningsrelease.htm)) |
| November 3, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000058/ardx-20260930xexhibit991.htm)) |
| November 3, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-cell Lymphoma | completed | "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04628494?tab=results)) |
| November 2026 | [Lou064 (blinded) primary completion](https://sec-api.dev/pdufa/lou064-blinded) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT05677451 (24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677451)) |
| November 3, 2026 | [AD109 topline data readout](https://sec-api.dev/pdufa/ad109) | APMD | OSA | completed | "NCT05811247 (Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Apnimed; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811247?tab=results)) |
| November 3, 2026 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Prader-Willi Syndrome; Obesity; Hyperphagia | completed | "NCT06772597 (A Study of Setmelanotide in Patients With Prader-Willi Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-03 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06772597)) |
| November 4, 2026 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000119312526447290/adpt-ex99_1.htm)) |
| November 4, 2026 | [Odyssey Therapeutics, Inc. earnings report](https://sec-api.dev/companies/odtx/catalysts) | ODTX |  | completed | "Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1882782/000119312526446174/odtx-ex99_1.htm)) |
| November 4, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526447235/dsgn-ex99_1.htm)) |
| November 4, 2026 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526446203/d188608dex991.htm)) |
| November 4, 2026 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000119312526447357/opk-ex99_1.htm)) |
| November 4, 2026 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Therapeutics Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000110465926122403/tm2628880d1_ex99-1.htm)) |
| November 4, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm)) |
| November 4, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "— Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926122654/tm2628556d1_ex99-1.htm)) |
| November 4, 2026 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000056/a2026q38kexhibit991.htm)) |
| November 4, 2026 | [Kailera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klra/catalysts) | KLRA |  | completed | "Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2096997/000119312526447232/ck0002096997-ex99_1.htm)) |
| November 4, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828026070150/q32026eolsex991.htm)) |
| November 4, 2026 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "ANN ARBOR, MI / ACCESSWIRE / November 4, 2026 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the three and nine months ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495426009511/zom_ex991.htm)) |
| November 4, 2026 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| November 4, 2026 | [RAP-219 topline data readout](https://sec-api.dev/pdufa/rap-219) | RAPP | bipolar mania | completed, positive | "BOSTON and SAN DIEGO, November 4, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including a summary of the recently announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania and updates across the RAP-219 development program and pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000119312526446202/rapp-ex99_1.htm)) |
| November 4, 2026 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000119312526447247/okur-ex99_1.htm)) |
| November 4, 2026 | [RAP-219 earnings report](https://sec-api.dev/pdufa/rap-219) | RAPP |  | completed | "BOSTON and SAN DIEGO, November 4, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including a summary of the recently announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania and updates across the RAP-219 development program and pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000119312526446202/rapp-ex99_1.htm)) |
| November 4, 2026 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q3 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)) |
| November 4, 2026 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000045/lfcr-2026q3xex991earningsr.htm)) |
| November 4, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm)) |
| November 4, 2026 | [UGN-501 trial start](https://sec-api.dev/pdufa/ugn-501) | URGN |  | completed | "Announced first patient dosed in the UGN-501 Phase 1 trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| November 4, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126041959/ef20084542_ex99-1.htm)) |
| November 4, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526447276/acad-ex99_1.htm)) |
| November 4, 2026 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "Pharma Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465926122360/tm2628939d1_ex99-1.htm)) |
| November 4, 2026 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "PRINCETON, N.J., Nov. 4, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2026, and provided an overview of recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| November 4, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm)) |
| November 4, 2026 | [NATURES SUNSHINE PRODUCTS INC earnings report](https://sec-api.dev/companies/natr/catalysts) | NATR |  | completed | "Nature's Sunshine Reports Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/275053/000162828026070297/natrq32026earningsrelease.htm)) |
| November 4, 2026 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000160/cy26q3ex991pressrelease.htm)) |
| November 4, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm)) |
| November 4, 2026 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000119312526447273/tnya-ex99_1.htm)) |
| November 4, 2026 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526447250/rlay-ex99_1.htm)) |
| November 4, 2026 | [OCU410 trial start](https://sec-api.dev/pdufa/ocu410) | OCGN |  | completed | "Announced the first patient dosed in ArMaDa3, a 240-subject global Phase 3 trial randomizing patients 2:1 to a single subretinal injection of OCU410 or untreated control across the U.S., Canada, and Europe; the primary endpoint is GA lesion growth over 12 months" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm)) |
| November 4, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000036/uthrq32026-ex991.htm)) |
| November 4, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm)) |
| November 4, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "Harmony Biosciences Reports Q3 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm)) |
| November 4, 2026 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "Charles River Laboratories Announces Third-Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000156/crl3q26earningsrelease.htm)) |
| November 4, 2026 | [Ivonescimab earnings report](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed | "1 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit's Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab's Potential Ivonescimab Global Clinical Development Program Continues to Grow with New Studies in Bladder and Kidney Cancers Ivonescimab Regimens Demonstrate Statistically Significant Overall Survival Benefits Versus Pembrolizumab in PD-L1-Positive Advanced NSCLC and Versus Durvalumab Plus Chemotherapy in Biliary Tract Cancer in Akeso's Phase III Studies Conducted in China Summit Closes Third Quarter with $629.8 Million in Cash and Investments and Received $2.0 Billion from AstraZeneca in Connection with an Equity Investment Post Third Quarter Miami, Florida, November 4, 2026 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000088/a2026_prx1105xq32026earn.htm)) |
| November 4, 2026 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010326016970/dp256359_ex9901.htm)) |
| November 4, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000075/sdgr-20260930x8kxexx991.htm)) |
| November 4, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526447366/d177079dex991.htm)) |
| November 4, 2026 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828026070161/lyel-20261104x8kexx991.htm)) |
| November 4, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926034775/ex_1007139.htm)) |
| November 4, 2026 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm)) |
| November 4, 2026 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000062/xncr-20261104xexx991.htm)) |
| November 4, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Announces Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm)) |
| November 4, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)) |
| November 4, 2026 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312526446183/qttb-ex99_1.htm)) |
| November 4, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526446185/d166389dex991.htm)) |
| November 4, 2026 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312526447193/rvmd-ex99_1.htm)) |
| November 4, 2026 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828026070148/a20261104-q3ex991earningsr.htm)) |
| November 4, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "Royalty Pharma reports third quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000026/rprx-20260930rpplcpressxre.htm)) |
| November 4, 2026 | [Zw25 (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zw25-zanidatamab) | JAZZ |  | completed | "NCT03929666 (A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-30 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03929666?tab=results)) |
| November 4, 2026 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | AZN | Thrombotic Microangiopathy | completed | "NCT04543591 (Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04543591?tab=results)) |
| November 4, 2026 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | IgA Nephropathy | completed | "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578834?tab=results)) |
| November 4, 2026 | [KLU156 topline data readout](https://sec-api.dev/pdufa/klu156) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT05842954 (Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842954?tab=results)) |
| November 4, 2026 | [TAK-279 topline data readout](https://sec-api.dev/pdufa/tak-279) | TAK | Generalized Pustular Psoriasis; Erythrodermic Psoriasis | completed | "NCT06323356 (A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323356?tab=results)) |
| November 4, 2026 | [0.412% stannous fluoride toothpaste and flat trimmed toothbrush primary completion](https://sec-api.dev/pdufa/0-412-stannous-fluoride-toothpaste-and-flat-trimmed-toothbrush) | CL | Plaque; Gingivitis | completed | "NCT07917507 (Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-11-04 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07917507)) |
| November 5, 2026 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000056/ex-9913q2026earningsrelease.htm)) |
| November 5, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "CITY, Calif., November 5, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123336/tm2628931d2_ex99-1.htm)) |
| November 5, 2026 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000119312526449791/sana-ex99_1.htm)) |
| November 5, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000021/nvax3q26earningspressrelea.htm)) |
| November 5, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_1.htm)) |
| November 5, 2026 | [DA-1726 interim data readout](https://sec-api.dev/pdufa/da-1726) | MTVA |  | completed, positive | "CAMBRIDGE, Mass., November 5, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive interim data from Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926123110/mtva-ex99d1.htm)) |
| November 5, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm)) |
| November 5, 2026 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926123029/tm2629044d1_ex99-1.htm)) |
| November 5, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000083/q32026pr.htm)) |
| November 5, 2026 | [Ebribafusp alfa trial start](https://sec-api.dev/pdufa/ebribafusp-alfa) | AKBA |  | completed | "•In September, Akebia announced it had dosed the first patient in a Phase 2 open-label basket trial of ebribafusp alfa, which Akebia believes has the potential to be a next-generation complement inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000083/q32026pr.htm)) |
| November 5, 2026 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000063/entradatherapeuticsq32026e.htm)) |
| November 5, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926123039/acrs-ex99d1.htm)) |
| November 5, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526449743/mnkd-ex99_1.htm)) |
| November 5, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Third-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)) |
| November 5, 2026 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces Q3 2026 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000119312526449787/ctmx-ex99_1.htm)) |
| November 5, 2026 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594726000055/exhibit991fy27-q2earningsr.htm)) |
| November 5, 2026 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000065/acet-ex99_1.htm)) |
| November 5, 2026 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000175913826000046/caba-ex99_1.htm)) |
| November 5, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526448525/amlx-ex99_1.htm)) |
| November 5, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926035275/ex_1039446.htm)) |
| November 5, 2026 | [PRECISION BIOSCIENCES INC trial start](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "On November 5, 2026, the Company also issued a press release to announce the first patient dosed with PBGENE-DMD completed the eight week observation period following treatment with no reported safety concerns, including no serious adverse events or adverse events of special interest (the "DMD News Release" and, together with the HBV News Release, the "News Releases")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026070542/dtil-20261105.htm)) |
| November 5, 2026 | [PH-762 earnings report](https://sec-api.dev/pdufa/ph-762) | PHIO |  | completed | "Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000143774926035277/ex_1033232.htm)) |
| November 5, 2026 | [Korsana Biosciences, Inc. earnings report](https://sec-api.dev/companies/krsa/catalysts) | KRSA |  | completed | "Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1755237/000119312526448535/krsa-ex99_1.htm)) |
| November 5, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000143/ex991q320268-k.htm)) |
| November 5, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526448530/fate-ex99_1.htm)) |
| November 5, 2026 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000162828026070585/coll-2026x09x30xex99x1.htm)) |
| November 5, 2026 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000076/atyr-ex99_1.htm)) |
| November 5, 2026 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, November 5, 2026 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today reported financial results for the three months ended September 30, 2026, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282226000124/pressreleaseearningsq311-0.htm)) |
| November 5, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm)) |
| November 5, 2026 | [Lipocine Inc. earnings report](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Announces Financial Results for the Third Quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226050098/ex99-1.htm)) |
| November 5, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526448527/glue-ex99_1.htm)) |
| November 5, 2026 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000119312526449813/alec-ex99_1.htm)) |
| November 5, 2026 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000110/exhibit991_earningsrelease.htm)) |
| November 5, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026070622/ex991earningsreleaseq32026.htm)) |
| November 5, 2026 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465926123316/elut-ex99d1.htm)) |
| November 5, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm)) |
| November 5, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001439/e665874_ex99-1.htm)) |
| November 5, 2026 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148926000035/vtvt-20260930xexx991pressr.htm)) |
| November 5, 2026 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000020/nktx-ex99_1.htm)) |
| November 5, 2026 | [MIMRYLO™ (rusfertide) FDA approval](https://sec-api.dev/pdufa/rusfertide) | PTGX | erythrocytosis in adults with polycythemia vera | completed, approved | "Protagonist announced that its partner Takeda received U.S. Food and Drug Administration (FDA) approval of MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera (PV)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm)) |
| November 5, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000077/anip-20261105xexx991.htm)) |
| November 5, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526449748/spry-ex99_1.htm)) |
| November 5, 2026 | [LB PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lbrx/catalysts) | LBRX |  | completed | "LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1691082/000119312526449887/d167920dex991.htm)) |
| November 5, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000171034026000006/eton-2026q332026xexx991.htm)) |
| November 5, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026070613/sttk_3q2026earningsrelease.htm)) |
| November 5, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526449822/srpt-ex99_1.htm)) |
| November 5, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., November 5, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-2026115x8kex991.htm)) |
| November 5, 2026 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000119312526448604/pyxs-ex99_1.htm)) |
| November 5, 2026 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526450210/revb-ex99_1.htm)) |
| November 5, 2026 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312526448556/clym-ex99_1.htm)) |
| November 5, 2026 | [Quoin Pharmaceuticals Ltd. earnings report](https://sec-api.dev/companies/qnrx/catalysts) | QNRX |  | completed | "Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_ex99-1.htm)) |
| November 5, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526449790/janx-ex99_1.htm)) |
| November 5, 2026 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) label expansion decision](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, approved | "BLA761433 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20261105, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761433%22)) |
| November 5, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526449985/gyre-ex99_1.htm)) |
| November 5, 2026 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "Dogwood Therapeutics Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000110465926123095/dwtx-ex99d1.htm)) |
| November 5, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312526449831/orgo-ex99_1.htm)) |
| November 5, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526449780/vera-ex99_1.htm)) |
| November 5, 2026 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828026071022/ex991earningspr.htm)) |
| November 5, 2026 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526449819/elvn-ex99_1.htm)) |
| November 5, 2026 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905326000030/exhibit991q32026earningsre.htm)) |
| November 5, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm)) |
| November 5, 2026 | [Cancer earnings report](https://sec-api.dev/pdufa/cancer) | ALLO |  | completed | "SOUTH SAN FRANCISCO, Calif., November 5, 2026 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000162828026071040/allo-20260930xexx991q326.htm)) |
| November 5, 2026 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000065/exhibit991q32026.htm)) |
| November 5, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| November 5, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter 2026 financial results, business achievements, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926123030/tm2628901d1_ex99-1.htm)) |
| November 5, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000051/amph-ex99d1.htm)) |
| November 5, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326007150/exh_991.htm)) |
| November 5, 2026 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000068/ints20261105ex99120260930p.htm)) |
| November 5, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000062/rigl-20261105xex991q32026r.htm)) |
| November 5, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526448711/iron-ex99_1.htm)) |
| November 5, 2026 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000119312526449820/inab-ex99_1.htm)) |
| November 5, 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 5, 2026 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000119312526450008/bioa-ex99_1.htm)) |
| November 5, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526448559/rgnx-ex99_1.htm)) |
| November 5, 2026 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528026000048/exhibit99q32026.htm)) |
| November 5, 2026 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "1 C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab; Progressing Additional Cohorts with Data from All Evaluated Cohorts Expected in Mid-2027 Phase 1b Trial of Cemsidomide in Combination with Approved Standard of Care Multiple Myeloma Therapies On Track to Initiate in 1H 2027 WATERTOWN, Mass., November 5, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the third quarter ended September 30, 2026, as well as recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828026070560/exhibit991q32026earnings.htm)) |
| November 5, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., November 5, 2026 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 5, 2026 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000119312526448517/d33477dex991.htm)) |
| November 5, 2026 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070469/exhibit991-q32026earningsr.htm)) |
| November 5, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000114/exh991q32026earningsrelease.htm)) |
| November 5, 2026 | [RYZUMVI (ryzumvi) FDA approval](https://sec-api.dev/pdufa/ryzumvi) | VTRS | presbyopia in adults | completed, approved | "•In October, the Company announced that the FDA approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)) |
| November 5, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526448637/agen-ex99_1.htm)) |
| November 5, 2026 | [NEONC TECHNOLOGIES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/nthi/catalysts) | NTHI |  | completed | "NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912626012024/neonctechnologies_ex99-1.htm)) |
| November 5, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000065/q3earningspr11-5x26final.htm)) |
| November 5, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex991earnin.htm)) |
| November 5, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000060/crbu-20261105xexx991.htm)) |
| November 5, 2026 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465926123381/tm2629096d1_ex99-1.htm)) |
| November 2026 | [Parsaclisib primary completion](https://sec-api.dev/pdufa/parsaclisib) | INCY | B-Cell Malignancies | scheduled | "NCT04509700 (Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04509700)) |
| November 5, 2026 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06333808?tab=results)) |
| November 6, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000011/cgon-20261106x8kexx991.htm)) |
| November 6, 2026 | [OneMedNet Corp earnings report](https://sec-api.dev/companies/onmd/catalysts) | ONMD |  | completed | "AI-driven Real-World Data (RWD), today announced preliminary revenue results for the third quarter ended September 30, 2026, and provides revenue guidance for the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1849380/000149315226050362/ex99-1.htm)) |
| November 6, 2026 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Elanco Animal Health Reports Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910426000054/elanco-20260930exhibit991.htm)) |
| November 6, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926124484/tm2629343d1_ex99-1.htm)) |
| November 6, 2026 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184326007214/exh_991.htm)) |
| November 6, 2026 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000149315226050541/ex99-1.htm)) |
| November 6, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm)) |
| November 6, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000194/exhibit9912026q3pressrelea.htm)) |
| November 6, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports third quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000034/pressrelease-q32026.htm)) |
| November 6, 2026 | [Vogenx, Inc. earnings report](https://sec-api.dev/companies/vogx/catalysts) | VOGX |  | completed | "Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced its financial results for the third quarter and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1903784/000118518526005214/vogenxex99-1.htm)) |
| November 6, 2026 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Announces Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326005056/exhibit_99-1.htm)) |
| November 2026 | [Pluvicto primary completion](https://sec-api.dev/pdufa/pluvicto) | NVS | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06004661 (Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06004661)) |
| November 6, 2026 | [Rmenb+omv nz vaccine topline data readout](https://sec-api.dev/pdufa/rmenb-omv-nz-vaccine) | GSK | Meningitis | completed | "NCT06995430 (A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-11-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06995430?tab=results)) |
| November 9, 2026 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Harrow Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000162828026072195/hrow-20261109xpressrelease.htm)) |
| November 9, 2026 | [AbCellera Biologics Inc. earnings report](https://sec-api.dev/companies/abcl/catalysts) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000058/q32026earningspressrelease.htm)) |
| November 9, 2026 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000067/ex991q32026_earningsxrelea.htm)) |
| November 9, 2026 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026071886/bicara-3q26earningspr.htm)) |
| November 9, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526452721/hrtx-ex99_1.htm)) |
| November 9, 2026 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000149315226050621/ex99-01.htm)) |
| November 9, 2026 | [ZEVASKYN (zevaskyn) earnings report](https://sec-api.dev/pdufa/zevaskyn) | ABEO |  | completed | "Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226050609/ex99-1.htm)) |
| November 9, 2026 | [JANX011 interim data readout](https://sec-api.dev/pdufa/janx011) | JANX |  | scheduled | "Initial clinical data from the study will be presented during an investor webcast on November 9, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526449790/janx-ex99_1.htm)) |
| November 9, 2026 | [TG THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tgtx/catalysts) | TGTX |  | completed | "TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000162828026071870/q3-26earningsprxexx991.htm)) |
| November 9, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm)) |
| November 9, 2026 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312526453636/d177149dex991.htm)) |
| November 9, 2026 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516026000069/zntlq32026pressrelease.htm)) |
| November 9, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "November 9, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097/ibrx-2026119x8kexhibit991.htm)) |
| November 9, 2026 | [Attovia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/atto/catalysts) | ATTO |  | completed | "Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2058707/000119312526453592/atto-ex99_1.htm)) |
| November 9, 2026 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earningsrelease.htm)) |
| November 9, 2026 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000119312526452660/antx-ex99_1.htm)) |
| November 9, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| November 9, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm)) |
| November 9, 2026 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports third quarter 2026 financial results and highlights progress on key programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126042598/ef20085128_ex99-1.htm)) |
| November 9, 2026 | [Turn Therapeutics Inc. earnings report](https://sec-api.dev/companies/ttrx/catalysts) | TTRX |  | completed | "Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023016/000121390026117180/ea031139901ex99-1.htm)) |
| November 9, 2026 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Q3 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm)) |
| November 9, 2026 | [Veradermics, Inc topline data readout](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed, positive | "On November 9, 2026, the Company announced positive topline results from Part B of its randomized, double-blind, placebo-controlled, registration-directed Phase 2/3 clinical trial (Study '302') evaluating VDPHL01, an investigational, proprietary, extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000038/mane-20261109.htm)) |
| November 9, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126042783/ef20085184_ex99-1.htm)) |
| November 9, 2026 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000119312526452707/sprb-ex99_1.htm)) |
| November 9, 2026 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000119312526453641/srzn-ex99_1.htm)) |
| November 9, 2026 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MD, November 10, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2026 financial results and raised its 2026 total revenue guidance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/tm2629420d1_ex99-1.htm)) |
| November 9, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-1.htm)) |
| November 9, 2026 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000119312526452716/mreo-ex99_1.htm)) |
| November 9, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm)) |
| November 9, 2026 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000119312526453670/trvi-ex99_1.htm)) |
| November 9, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526452704/whwk-ex99_1.htm)) |
| November 9, 2026 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the First Quarter Fiscal 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000119312526453570/lfvn-ex99_1.htm)) |
| November 9, 2026 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - November 9, 2026 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today provided a business update and announced results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000119312526453708/catx-ex99_1.htm)) |
| November 9, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm)) |
| November 9, 2026 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526453553/mbx-ex99_1.htm)) |
| November 9, 2026 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "Editas Medicine Announces Third Quarter 2026 Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000100/editasmedicinepressrelease.htm)) |
| November 9, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026071899/adct-20260930pressrelease.htm)) |
| November 9, 2026 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326007256/exh_991.htm)) |
| November 9, 2026 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000119312526452620/aura-ex99_1.htm)) |
| November 9, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm)) |
| November 9, 2026 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000130/q2fy2026roivantearningsrel.htm)) |
| November 9, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526452635/tngx-ex99_1.htm)) |
| November 9, 2026 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "York, November 9, 2026 - KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000182912626012118/kalabio_ex99-1.htm)) |
| November 9, 2026 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312526453547/sepn-ex99_1.htm)) |
| November 9, 2026 | [ImageneBio, Inc. earnings report](https://sec-api.dev/companies/ima/catalysts) | IMA |  | completed | "ImageneBio Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835579/000119312526453639/d139863dex991.htm)) |
| November 9, 2026 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453557/annx-ex99_1.htm)) |
| November 9, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526453804/rani-ex99_1.htm)) |
| November 9, 2026 | [NKX019 interim data readout](https://sec-api.dev/pdufa/nkx019) | NKTX | autoimmune diseases, today | completed, positive | "SOUTH SAN FRANCISCO, Calif., November 9, 2026 — Nkarta (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced positive initial clinical data from its Ntrust clinical trial program evaluating NKX019, its allogeneic, off-the-shelf CAR NK cell therapy candidate." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000027/nktx-ex99_1.htm)) |
| November 9, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm)) |
| November 9, 2026 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Overweight or Obesity; CKD; Type 2 Diabetes | completed | "NCT05936151 (A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05936151?tab=results)) |
| November 10, 2026 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000119312526454473/coya-ex99_1.htm)) |
| November 10, 2026 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm)) |
| November 10, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526454454/d164715dex991.htm)) |
| November 10, 2026 | [CITY THERAPEUTICS, INC. trial start](https://sec-api.dev/companies/cty/catalysts) | CTY | Stargardt Disease | completed | "Mass., November 10, 2026 - City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, today announced that the first participant has been dosed in the Phase 1 clinical trial of CITY-RBP4, an investigational RNAi therapeutic candidate for the treatment of Stargardt disease type 1 (Stargardt disease)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2143850/000110465926124775/tm2629408d1_ex99-1.htm)) |
| November 10, 2026 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000141/autlex-991pr111026.htm)) |
| November 10, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm)) |
| November 10, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926125188/nxtc-ex99d1.htm)) |
| November 10, 2026 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312526454449/xlo-ex99_1.htm)) |
| November 10, 2026 | [PALI-2108 earnings report](https://sec-api.dev/pdufa/pali-2108) | PALI |  | completed | "Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000025/pali-ex99_1.htm)) |
| November 10, 2026 | [Cardiff Oncology, Inc. earnings report](https://sec-api.dev/companies/crdf/catalysts) | CRDF |  | completed | "Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000119312526458500/crdf-ex99_1.htm)) |
| November 10, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000030/exhibit991-earningsrelease.htm)) |
| November 10, 2026 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000119312526454476/crbp-ex99_1.htm)) |
| November 10, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526454430/ck0001534133-ex99_1.htm)) |
| November 10, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/srrk-ex99_1.htm)) |
| November 10, 2026 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Reports Financial Results for the Third Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226050964/ex99-1.htm)) |
| November 10, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm)) |
| November 10, 2026 | [Hemab Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/coag/catalysts) | COAG |  | completed | "Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2114044/000119312526454414/d22670dex991.htm)) |
| November 10, 2026 | [Braveheart Bio, Inc. earnings report](https://sec-api.dev/companies/brve/catalysts) | BRVE |  | completed | "Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2131524/000162828026072702/brve-q3268xkex991xearnings.htm)) |
| November 10, 2026 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000119312526454405/upb-ex99_1.htm)) |
| November 10, 2026 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending November 10, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1016504/000143774925034076/inbp20250930_10q.htm)) |
| November 10, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526455416/kura-ex99_1.htm)) |
| November 10, 2026 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. Announces Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000110465926124793/vreof-ex99d1.htm)) |
| November 10, 2026 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/ibio-ex99d1.htm)) |
| November 10, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, November 10, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926124761/plx-ex99d1.htm)) |
| November 10, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526454474/tyra-ex99_1.htm)) |
| November 10, 2026 | [MGX-001 earnings report](https://sec-api.dev/pdufa/mgx-001) | MGX |  | completed | "Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000119312526455436/mgx-ex99_1.htm)) |
| November 10, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926124790/tm2629430d1_ex99-1.htm)) |
| November 10, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, November 10, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454403/olma-ex99_1.htm)) |
| November 10, 2026 | [BridgeBio Oncology Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bbot/catalysts) | BBOT |  | completed | "BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/bbot-ex99_1.htm)) |
| November 10, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/goss-20261110xexx991xearni.htm)) |
| November 10, 2026 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000162828026072497/sion3q26earningsrelease.htm)) |
| November 10, 2026 | [Symvess (symvess) earnings report](https://sec-api.dev/pdufa/symvess) | HUMA |  | completed | "Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000119312526454402/huma-ex99_1.htm)) |
| November 10, 2026 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000119312526454486/atos-ex99_1.htm)) |
| November 10, 2026 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125171/tmb-ex99d1.htm)) |
| November 10, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926124770/tm2629427d1_ex99-1.htm)) |
| November 10, 2026 | [Karyopharm Therapeutics Inc. PDUFA date](https://sec-api.dev/companies/kpti/catalysts) | KPTI |  | scheduled | "The Company expects to receive a filing communication, or Day-74 Letter, from the FDA on or about November 10, 2026, which will include the Prescription Drug User Fee Act target action date and other pertinent information." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/d141618d8k.htm)) |
| November 10, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526454467/pmvp-ex99_1.htm)) |
| November 10, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072493/ird-20261110xex991.htm)) |
| November 10, 2026 | [Release (release) complete response letter (CRL)](https://sec-api.dev/pdufa/release) | CING |  | completed, complete response letter | "November 10, 2026, Cingulate Inc. (Company) issued a press release announcing that its Chairman and CEO, Shane J. Schaffer, in an interview on Innovators with Jane King discusses the Company's ongoing efforts to address the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding the CTx-1301 new drug application (NDA), progress made to date, and the anticipated timeline for NDA resubmission." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226050870/form8-k.htm)) |
| November 10, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926125159/ganx-ex99d1.htm)) |
| November 10, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000030/ino-93026x8kex991.htm)) |
| November 10, 2026 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312526454469/pepg-ex99_1.htm)) |
| November 10, 2026 | [NRX Pharmaceuticals, Inc. PDUFA date](https://sec-api.dev/companies/nrxp/catalysts) | NRXP |  | scheduled | "The acknowledgement letter revised the GDUFA goal date to November 10, 2026, citing that the reclassified amendment will not require a substantial expenditure of FDA resources." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/nrxp20260915_8k.htm)) |
| November 10, 2026 | [Imatinib earnings report](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm)) |
| November 10, 2026 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184326007311/exh_991.htm)) |
| November 10, 2026 | [PepGen Inc. topline data readout](https://sec-api.dev/companies/pepg/catalysts) | PEPG | myotonic dystrophy type 1 | completed, positive | "BOSTON-- November 10, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced positive topline results from the 10 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial (NCT06667453) evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1), a rare, progressive, and multisystemic genetic disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312526454469/pepg-ex99_2.htm)) |
| November 10, 2026 | [Veradermics, Inc earnings report](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed | "Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000041/ex991q326earnings.htm)) |
| November 10, 2026 | [Zulresso (brexanolone) trial start](https://sec-api.dev/pdufa/brexanolone) | LPCN |  | completed | "LAKE CITY, November 10, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company's Phase 3 study evaluating" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226050842/ex99-1.htm)) |
| November 10, 2026 | [CUMBERLAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/cpix/catalysts) | CPIX |  | completed | "(Nov. 10, 2026) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today its third quarter 2026 financial results and provided a company update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/a2026q3-ex991er.htm)) |
| November 10, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | completed | "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226752?tab=results)) |
| November 2026 | [Prgn-2009 plus pembrolizumab primary completion](https://sec-api.dev/pdufa/prgn-2009-plus-pembrolizumab) | PGEN | Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy | scheduled | "NCT06157151 (PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-11 (ESTIMATED); Lead Sponsor Precigen, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06157151)) |
| November 12, 2026 | [Kardigan, Inc. earnings report](https://sec-api.dev/companies/kard/catalysts) | KARD |  | completed | "Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2123613/000119312526456885/ck0002123613-ex99_1.htm)) |
| November 12, 2026 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000119312526456865/tcrx-ex99_1.htm)) |
| November 12, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526458403/bolt-ex99_1.htm)) |
| November 12, 2026 | [Akari Therapeutics Plc earnings report](https://sec-api.dev/companies/aktx/catalysts) | AKTX |  | completed | "Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1541157/000149315226051486/ex99-1.htm)) |
| November 12, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., November 12, 2026 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458637/spro-ex99_1.htm)) |
| November 12, 2026 | [Parabilis Medicines, Inc. earnings report](https://sec-api.dev/companies/pbls/catalysts) | PBLS |  | completed | "Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1657677/000119312526456892/ck0001657677-ex99_1.htm)) |
| November 12, 2026 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315226051414/ex99-1.htm)) |
| November 12, 2026 | [Aglatimagene trial start](https://sec-api.dev/pdufa/aglatimagene) | CADL | metastatic non-squamous NSCLC | completed | "As previously announced, the Company initiated the first clinical trial site of the global pivotal phase 3 clinical trial (AURORA) (NCT07660094), which is evaluating aglatimagene plus valacyclovir in combination with continued pembrolizumab in patients with metastatic non-squamous NSCLC whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526458316/cadl-ex99_1.htm)) |
| November 12, 2026 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774926036574/ex_1044180.htm)) |
| November 12, 2026 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774926036555/ex_1043772.htm)) |
| November 12, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926126260/pmn-ex99d1.htm)) |
| November 12, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926126274/armp-ex99d1.htm)) |
| November 12, 2026 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940726000077/arwr-202611128kex991.htm)) |
| November 12, 2026 | [Eikon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eikn/catalysts) | EIKN |  | completed | "Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1861123/000119312526456794/eikn-ex99_1.htm)) |
| November 12, 2026 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000069/ser-20261112xex991_earning.htm)) |
| November 12, 2026 | [Generate Biomedicines, Inc. earnings report](https://sec-api.dev/companies/genb/catalysts) | GENB |  | completed | "Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2100782/000119312526456921/ck0002100782-ex99_1.htm)) |
| November 12, 2026 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000017/yarw-q32026earningsrelease.htm)) |
| November 12, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526458379/eq-ex99_1.htm)) |
| November 12, 2026 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828026073372/q320268-kex991xpressrelease.htm)) |
| November 12, 2026 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS AND RECENT DEVELOPMENTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000149315226051601/ex99-1.htm)) |
| November 12, 2026 | [Avalyn Pharma Inc. earnings report](https://sec-api.dev/companies/avln/catalysts) | AVLN |  | completed | "Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540171/000119312526457053/ck0001540171-ex99_1.htm)) |
| November 12, 2026 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312526457040/kytx-ex99_1.htm)) |
| November 12, 2026 | [Evommune, Inc. earnings report](https://sec-api.dev/companies/evmn/catalysts) | EVMN |  | completed | "Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2044725/000119312526458329/evmn-ex99_1.htm)) |
| November 12, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926126209/tm2629579d1_ex99-1.htm)) |
| November 12, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026073409/pressrelease-livefile.htm)) |
| November 12, 2026 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, November 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000110465926125910/mgtx-ex99d1.htm)) |
| November 12, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126043434/ef20085455_ex99-1.htm)) |
| November 12, 2026 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000127/plrx-20261112xexx991.htm)) |
| November 12, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm)) |
| November 12, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526457060/d101909dex991.htm)) |
| November 12, 2026 | [BlossomHill Therapeutics, Inc. earnings report](https://sec-api.dev/companies/blsm/catalysts) | BLSM |  | completed | "BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1839970/000119312526458447/d389211dex991.htm)) |
| November 12, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526458316/cadl-ex99_1.htm)) |
| November 12, 2026 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Rockwell Medical Announces Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828026073052/a2026q326-earningsxpr.htm)) |
| November 12, 2026 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)) |
| November 12, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm)) |
| November 12, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, November 12, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000150/exhibit991-2026q310xqpr.htm)) |
| November 12, 2026 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000093/ex991-pressreleaseseptembe.htm)) |
| November 12, 2026 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "-- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110465926127041/tm2629651d1_ex99-1.htm)) |
| November 12, 2026 | [Obsidian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/obx/catalysts) | OBX |  | completed | "Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2130606/000119312526458347/d20599dex991.htm)) |
| November 12, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026118964/ea031199801ex99-1.htm)) |
| November 12, 2026 | [ADARx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/adrx/catalysts) | ADRX |  | completed | "ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)) |
| November 12, 2026 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390026119052/ea031194401ex99-1.htm)) |
| November 12, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926036647/ex_1042036.htm)) |
| November 12, 2026 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Third Quarter 2026 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000119312526458350/eras-ex99_1.htm)) |
| November 12, 2026 | [Immix Biopharma, Inc. earnings report](https://sec-api.dev/companies/immx/catalysts) | IMMX |  | completed | "Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873835/000149315226051402/ex99-1.htm)) |
| November 12, 2026 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "-- Azora Therapeutics, Inc. (Nasdaq: AZR) ("Azora" or the "Company"), a biopharmaceutical company developing locally acting treatments for serious immune-mediated and inflammatory diseases, today provided a business update and reported its financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390026118922/ea031195201ex99-1.htm)) |
| November 12, 2026 | [RELMADA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/rlmd/catalysts) | RLMD |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000121390026118933/ea031205701ex99-1.htm)) |
| November 12, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - November 12, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended September 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000051/aztrpressrelease9302026-ex.htm)) |
| November 12, 2026 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000119312526457244/inkt-ex99_1.htm)) |
| November 12, 2026 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm)) |
| November 12, 2026 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000119312526458314/asmb-ex99_1.htm)) |
| November 12, 2026 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000053/twst-2026930xex991.htm)) |
| November 12, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526458378/eldn-ex99_1.htm)) |
| November 12, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226051484/ex99-1.htm)) |
| November 12, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000134/pths-pressreleasex20261112.htm)) |
| November 12, 2026 | [Aktis Oncology, Inc. earnings report](https://sec-api.dev/companies/akts/catalysts) | AKTS |  | completed | "Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2035832/000119312526457045/ck0002035832-ex99_1.htm)) |
| November 12, 2026 | [BioStem Technologies, Inc. earnings report](https://sec-api.dev/companies/bsem/catalysts) | BSEM |  | completed | "BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658678/000119312526458305/bsem-ex99_1.htm)) |
| November 12, 2026 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000119312526458377/lctx-ex99_1.htm)) |
| November 12, 2026 | [Atrium Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rna/catalysts) | RNA |  | completed | "Atrium Therapeutics Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2093101/000119312526458459/d692180dex991.htm)) |
| November 12, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces Second Quarter 2027 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126043308/ef20085030_ex99-1.htm)) |
| November 12, 2026 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526458641/stro-ex99_1.htm)) |
| November 12, 2026 | [Scribe Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sctx/catalysts) | SCTX |  | completed | "Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853921/000119312526458486/sctx-ex99_1.htm)) |
| November 12, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, November 12, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926036385/ex_1043550.htm)) |
| November 12, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/sls-202611128xkexhibit991.htm)) |
| November 12, 2026 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000119312526458470/prok-ex99_1.htm)) |
| November 12, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CORMEDIX THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000063/crmd_q32026earningspr.htm)) |
| November 12, 2026 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm)) |
| November 12, 2026 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465926125830/tm2629581d1_ex99-1.htm)) |
| November 12, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226051202/ex99-1.htm)) |
| November 12, 2026 | [ANAPTYSBIO, INC earnings report](https://sec-api.dev/companies/anab/catalysts) | ANAB |  | completed | "Anaptys Reports Fiscal First Quarter 2027 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000119312526458461/anab-ex99_1.htm)) |
| November 12, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000074/exhibit99-1earningspressre.htm)) |
| November 12, 2026 | [CV Sciences, Inc. earnings report](https://sec-api.dev/companies/cvsi/catalysts) | CVSI |  | completed | "CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1510964/000119312526458290/cvsi-ex99_1.htm)) |
| November 12, 2026 | [Electra Therapeutics, Inc. earnings report](https://sec-api.dev/companies/etra/catalysts) | ETRA |  | completed | "Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2088082/000119312526458464/etra-ex99_1.htm)) |
| November 12, 2026 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "Minneapolis, Minnesota - November 12, 2026 (Business Wire) - DiaMedica Therapeutics Inc. ("DiaMedica" or the "Company") (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774926036600/ex_1044414.htm)) |
| November 12, 2026 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "HAYWARD, Calif., Nov.13, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its first fiscal quarter ended September 30, 2026, and provided an update on recent clinical data presentations." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312526459339/bntc-ex99_1.htm)) |
| November 12, 2026 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926125912/tm2629526d1_ex99-1.htm)) |
| November 12, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)) |
| November 12, 2026 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces Third Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000067/alt-ex99d1.htm)) |
| November 12, 2026 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Obesity; Genetic Obesity | completed | "NCT05093634 (EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05093634?tab=results)) |
| November 12, 2026 | [Yescarta (axicabtagene ciloleucel) topline data readout](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed or Refractory Large B-cell Lymphoma | completed | "NCT05459571 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05459571?tab=results)) |
| November 2026 | [Pf-07275315 dose 1 primary completion](https://sec-api.dev/pdufa/pf-07275315) | PFE | Atopic Dermatitis | scheduled | "NCT05995964 (A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-12 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995964)) |
| November 13, 2026 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312526459311/hura-ex99_1.htm)) |
| November 13, 2026 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| November 13, 2026 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000149315226051749/ex99-1.htm)) |
| November 13, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm)) |
| November 13, 2026 | [TRex Bio, Inc. earnings report](https://sec-api.dev/companies/trxb/catalysts) | TRXB |  | completed | "TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526460588/ck0002139097-ex99_1.htm)) |
| November 13, 2026 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "T-cell ("CAR-T") product candidates to treat cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000121390026119916/ea031215701ex99-1.htm)) |
| November 13, 2026 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926126519/tm2629645d1_ex99-1.htm)) |
| November 13, 2026 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326007431/exh_991.htm)) |
| November 13, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "Tvardi Therapeutics Announces Third Quarter 2026 Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm)) |
| November 13, 2026 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000119312526459373/ck0001774857-ex99_1.htm)) |
| November 13, 2026 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000162828026073824/vtgn-20261112xex991.htm)) |
| November 13, 2026 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526459287/d157312dex991.htm)) |
| November 13, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000057/exhibit99109302026.htm)) |
| November 13, 2026 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000119312526460816/cldi-ex99_1.htm)) |
| November 13, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226051546/ex99-1.htm)) |
| November 13, 2026 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (November 13, 2026) - Integrated BioPharma, Inc. (OTCQX: INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774926036730/ex_1043877.htm)) |
| November 13, 2026 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036126043542/ef20085528_ex99-1.htm)) |
| November 13, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d1.htm)) |
| November 13, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126525/fbio-ex99d1.htm)) |
| November 13, 2026 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316826008650/xenetic_ex9901.htm)) |
| November 13, 2026 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000119312526460775/d190919dex991.htm)) |
| November 13, 2026 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315226051806/ex99-1.htm)) |
| November 13, 2026 | [Xenetic Biosciences, Inc. trial start](https://sec-api.dev/companies/xbio/catalysts) | XBIO | large B-cell lymphoma | completed | "Initiated Clinical Evaluation of DNase I in Combination with CAR T-Cell Therapy: Announced the first patient dosed in an investigator-initiated, Phase I (NCT07361224) clinical study evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma (LBCL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316826008650/xenetic_ex9901.htm)) |
| November 13, 2026 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED NOVEMBER 13, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390026119681/ea031220401ex99-1.htm)) |
| November 13, 2026 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000149315226051708/ex99-1.htm)) |
| November 13, 2026 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926127094/tm2629728d1_ex99-1.htm)) |
| November 13, 2026 | [Bimatoprost sr topline data readout](https://sec-api.dev/pdufa/bimatoprost-sr) | ABBV | Open-Angle Glaucoma; Ocular Hypertension | completed | "NCT03850782 (Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-11-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03850782?tab=results)) |
| November 2026 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431086)) |
| November 14, 2026 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | Symptomatic Obstructive HCM | scheduled | "MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM; Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm)) |
| November 14, 2026 | [IGALMI® (dexmedetomidine) PDUFA date](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | scheduled | "FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm)) |
| November 14, 2026 | [Ivonescimab PDUFA date](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed, complete response letter | "In January 2026, the FDA accepted for filing our BLA seeking approval of ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-TKI therapy and provided a PDUFA target action date of November 14, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm)) |
| November 15, 2026 | [Ivonescimab complete response letter (CRL)](https://sec-api.dev/pdufa/ivonescimab) | SMMT | with locally advanced or metastatic non-small cell lung cancer | completed, complete response letter | "On November 15, 2026, Summit Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has issued a Complete Response Letter ("CRL") regarding the Biologics License Application ("BLA") for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm)) |
| November 2026 | [Cytisinicline primary completion](https://sec-api.dev/pdufa/cytisinicline) | QUIT | Vaping Cessation | scheduled | "NCT07392125 (Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2026-11-15 (ESTIMATED); Lead Sponsor Achieve Life Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07392125)) |
| November 16, 2026 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "Reports Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326005216/exhibit_99-1.htm)) |
| November 16, 2026 | [Dasiglucagon topline data readout](https://sec-api.dev/pdufa/dasiglucagon) | NVO | Diabetes Mellitus, Type 1 | completed | "NCT06588504 (Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-20 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-11-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588504?tab=results)) |
| November 2026 | [AZD0901 primary completion](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer | scheduled | "NCT06219941 (AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06219941)) |
| November 2026 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Metastatic Castration Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06894511)) |
| November 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Sjögren's Syndrome | scheduled | "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05946941)) |
| November 2026 | [JNJ-95597528 primary completion](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Dermatitis, Atopic | scheduled | "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230860)) |
| November 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634877)) |
| November 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Moderate to Severe Asthma | scheduled | "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05851443)) |
| November 2026 | [Nimacimab primary completion](https://sec-api.dev/pdufa/nimacimab) | SKYE | Obesity | scheduled | "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577090)) |
| November 22, 2026 | [Savara Inc PDUFA date](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | scheduled | "The FDA determined that the Company's responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm)) |
| November 22, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | rare diseases, today | scheduled | "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm)) |
| November 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Colon | scheduled | "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567782)) |
| November 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06693895 (A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06693895)) |
| November 2026 | [Dtpa primary completion](https://sec-api.dev/pdufa/dtpa) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | scheduled | "NCT07596199 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596199)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease | scheduled | "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585787)) |
| November 2026 | [Tx000045- dose a primary completion](https://sec-api.dev/pdufa/tx000045) | TECX | Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction | scheduled | "NCT06616974 (A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Tectonic Therapeutic." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06616974)) |
| November 25, 2026 | [Venglustat PDUFA date](https://sec-api.dev/pdufa/venglustat) | SNY |  | scheduled | "The target action date for the FDA decision is November 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm)) |
| November 2026 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216079)) |
| November 2026 | [ZEJULA (niraparib) primary completion](https://sec-api.dev/pdufa/niraparib) | GSK | Neoplasms | scheduled | "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03981796)) |
| November 27, 2026 | [Ribitol PDUFA date](https://sec-api.dev/pdufa/ribitol) | BBIO |  | scheduled | "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| November 2026 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever Immunization | scheduled | "NCT07103148 (A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07103148)) |
| November 2026 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Menstrual Migraine | scheduled | "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641466)) |
| November 30, 2026 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 30, 2026 | [Povetacicept PDUFA date](https://sec-api.dev/pdufa/povetacicept) | VRTX | immunoglobulin A nephropathy | scheduled | "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| November 2026 | [NeuroPace Inc primary completion](https://sec-api.dev/companies/npce/catalysts) | NPCE | Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable | scheduled | "NCT05339126 (RNS System LGS Feasibility Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor NeuroPace." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05339126)) |
| November 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS | scheduled | "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438407)) |
| November 2026 | [AU-011 primary completion](https://sec-api.dev/pdufa/au-011) | AURA | Eye Cancer; Primary Cancer | scheduled | "NCT06643884 (Suprachoroidal Administration in Subjects With Metastases to the Choroid): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Aura Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643884)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Idiopathic Hypersomnia | scheduled | "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812078)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 2 | scheduled | "NCT06952699 (A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952699)) |
| November 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07081633)) |
| November 2026 | [Mr-130a-01 contraceptive transdermal patch, containing norelgestromin (ngmn) primary completion](https://sec-api.dev/pdufa/mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn) | VTRS | Contraception | scheduled | "NCT07365904 (Investigating Ovulation Inhibition for Use as a Contraceptive): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365904)) |
| November 2026 | [Oral bge-102 primary completion](https://sec-api.dev/pdufa/oral-bge-102) | BIOA | Obesity and Cardiovascular Risk | scheduled | "NCT07656727 (A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor BioAge Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07656727)) |

Other months: https://sec-api.dev/fda-calendar/2026-10 , https://sec-api.dev/fda-calendar/2026-12. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates November 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-11

```bibtex
@misc{secapidev_fda_calendar_2026_11_20261116,
  title        = {PDUFA dates November 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-11}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_11_20261116","title":"PDUFA dates November 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-11","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
